NCNA NuCana plc

17.11
-0.93  -5%
Previous Close 18.03
Open 18.95
Price To Book 5.15
Market Cap 551225730
Shares 32,226,000
Volume 32,772
Short Ratio
Av. Daily Volume 94,131

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019.
NUC-1031 (Acelarin)
Front-Line Treatment of Advanced Biliary Tract Cancer
Phase 1 additional data due 2019.
NUC-3373
Solid tumors
Phase 3 ongoing.
NUC-1031 (Acelarin)
Pancreatic cancer
Phase 2 interim data due 2019.
NUC-1031 (Acelarin)
Platinum-sensitive ovarian cancer
Phase 1 initial data due 2019.
NUC-3373
Colorectal Cancer
Phase 1 data due 2019.
NUC-7738
Solid tumors